Persistent retention of colitogenic CD4+ memory T cells causes inflammatory bowel diseases to become intractable

Inflammatory Bowel Diseases

Volumn 15, Issue 6, 2009, Pages 926-934

  Kanai, Takanori ^a   Nemoto, Yasuhiro ^b   Tomita, Takayuki ^a   Totsuka, Teruji ^b   Watanabe, Mamoru ^b   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Colitogenic memory CD4 T; IL 7; Inflammatory bowel disease

Indexed keywords

CD34 ANTIGEN; CD45RB ANTIGEN; CYCLOPHOSPHAMIDE; FINGOLIMOD; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 7; RAG2 PROTEIN; THYMOCYTE ANTIBODY;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; COLITIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG MECHANISM; ENTERITIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INTRACTABLE ENTERITIS; LEUKAPHERESIS; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REMISSION; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

BONE MARROW; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC MEMORY; INFLAMMATORY BOWEL DISEASES;

EID: 67650215944     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20738     Document Type: Article

References (47)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369:1641-1657.
4. Goudet P, Dozois RR, Kelly KA, et al. Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg. 2001;18:51-55.
5. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1424-1429.
6. + effector and memory T cell generation. Nat Immunol. 2003;4:835-842.
7. Sprent J, Surh CD. T cell memory. Annu Rev Immunol. 2002;20:551-579.
8. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol. 2005;6:873-879.
9. Wherry EJ, Teichgräber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225-234.
10. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2:251-262.
11. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239-245.
12. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439: 682-687.
13. Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007;15:143-146.
14. + T cells induce or protect from chronic intestinal inflammation in C. B-17 SCID mice. Int Immunol. 1993;5:1461-1471.
15. Totsuka T, Kanai T, Iiyama R, et al. Ameliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis. Gastroenterology 2003;124:410-421.
16. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
17. - effector memory T cells. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1051-1058.
18. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol. 2005;174:6571-6576.
19. Bradley LM, Haynes L, Swain SL. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol. 2005;26:172-176.
20. Surh CD, Boyman O, Purton JF, et al. Homeostasis of memory T cells. Immunol Rev. 2006;211:154-163.
21. Totsuka T, Kanai T, Nemoto Y, et al. IL-7 Is essential for the development and the persistence of chronic colitis. J Immunol. 2007;178:4737-4748.
22. Yamazaki M, Yajima T, Tanabe M, et al. Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol. 2003;171:1556-1563.
23. + mucosal T cells in mice. Am J Physiol Gastrointest Liver Physiol. 2005; 288:G745-754.
24. Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest. 1995;95:2945-2953.
25. Fujihashi K, Kawabata S, Hiroi T, et al. Interleukin 2 (IL-2) and interleukin 7 (IL-7) reciprocally induce IL-7 and IL-2 receptors on gamma delta T-cell receptor-positive intraepithelial lymphocytes. Proc Natl Acad Sci U S A. 1996;93:3613-3618.
26. Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med. 1998;187:389-402.
27. Riddell RH. Pathology of idiopathic inflammatory bowel disease. In: Sartor RB, Sandborn WJ, eds. Inflammatory Bowel Diseases. 6th ed. London: Elsevier; 2004:399-424.
28. Tomita T, Kanai T, Nemoto Y, et al. Systemic, but not intestinal, IL-7 is essential for the persistence of chronic colitis. J Immunol. 2008;180: 383-390.
29. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol. 2006;24:657-679.
30. + effector-memory T cells continuously recirculate in chronic colitic mice. Inflamm Bowel Dis. (in press).
31. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005; 108:308-319.
32. - effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol. 2006;291:G267-274.
33. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7:73-79.
34. + regulatory T cells is a suppressive site of intestinal inflammation. J Immunol. 2007;178:4937-4946.
35. Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol. 2005;26:360-366.
36. Lee SK, Surh CD. Role of interleukin-7 in bone and T-cell homeostasis. Immunol Rev. 2005;208:169-180.
37. + T cells may be a pathogenic reservoir for chronic colitis. Gastroenterology. 2007;132:176-189.
38. Namen AE, Lupton S, Hjerrild K, et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature. 1988;333:571-573.
39. Watanabe M, Watanabe N, Iwao Y, et al. The serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7. J Clin Immunol. 1997;17:282-292.
40. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov. 2006;5:197-209.
41. Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther. 2006;6:453-466.
42. + monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm Bowel Dis. 2007;13:284-290.
43. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-1140.
44. Sandborn WJ, Colombel JF, Enns R, et al. Evaluation of natalizumab as continuous therapy (ENACT-2) trial group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353: 1912-1925.
45. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-1826.
46. Blanco Y, Saiz A, Carreras E, et al. Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol. 2005;4:54-63.
47. Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 2005;128:552-563.